ClinicalTrials.gg
Active, not recruitingNCT06679985Updated Jul 15, 2026

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

A Phase 2 interventional study of Casdozokitug and Toripalimab in Hepatocellular Carcinoma, sponsored by Coherus Oncology, Inc.. Active, not recruiting at 44 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Coherus Oncology, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Planned enrollment
242nd of 775
72 · median 36
Started
2024
with 34 others
Phase 2
259 of 926
40 open now
Primary completion
2027-09
later than 131 of 244 live
Registered
854th of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 242nd largest by planned enrollment of the 775 interventional ones that give a count, is one of 35 that started in 2024, is one of 259 in phase 2, reaches primary completion later than 131 of the 244 other live ones, and was the 854th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Unresectable Hepatocellular Carcinoma
  • Locally Advanced Hepatocellular Carcinoma
  • Metastatic Hepatocellular Carcinoma
  • Casdozokitug
  • Toripalimab
  • Bevacizumab
  • HCC
  • Liver Cancer
  • IL-27
  • PD-1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Unresectable locally advanced or HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases criteria in cirrhotic participants.
  • Disease that is not amenable to curative surgical and/or locoregional therapies or progressive disease (PD) after surgical and/or locoregional therapies.
  • ≥ 1 (per v1.1) that is untreated.

Exclusion Criteria:

  • Has received prior systemic therapy for HCC.
  • Has previously received an anti-IL-27 antibody (Ab) or anti-IL-27-targeted therapy.
  • Has known fibrolamellar HCC histology, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
  • Has moderate or severe ascites.
  • Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).

Additional protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Arm A: Casdozokitug Lower Dose + Toripalimab + Bevacizumab

    Drug: Casdozokitug · Drug: Toripalimab · Drug: Bevacizumab

  • Experimental
    Arm B: Casdozokitug Higher dose + Toripalimab + Bevacizumab

    Drug: Casdozokitug · Drug: Toripalimab · Drug: Bevacizumab

  • Active comparator
    Arm C: Toripalimab + Bevacizumab

    Drug: Toripalimab · Drug: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: From date of first dose to 90 days after date of last dose (Up to approximately 27 months)

  2. Objective Response Rate (ORR) by Investigator Review According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. ORR by Investigator Review According to HCC Modified RECIST (mRECIST)

    Time frame: Up to approximately 2 years

  2. Duration of Response (DoR) by Investigator Review According to RECIST v1.1

    Time frame: Up to approximately 2 years

  3. DoR by Investigator Review According to HCC mRECIST

    Time frame: Up to approximately 2 years

  4. Progression-free Survival (PFS) by Investigator Review According to RECIST v1.1

    Time frame: Up to approximately 2 years

  5. PFS by Investigator Review According to HCC mRECIST

    Time frame: Up to approximately 2 years

  6. Disease Control Rate (DCR) by Investigator Review According to RECIST v1.1

    Time frame: Up to approximately 2 years

  7. DCR by Investigator Review According to HCC mRECIST

    Time frame: Up to approximately 2 years

  8. Overall Survival (OS)

    Time frame: Up to approximately 2 years

  9. Maximum Concentration (Cmax)

    Time frame: Up to approximately 25 months

  10. Minimum Concentration (Cmin)

    Time frame: Up to approximately 25 months

  11. Time to Cmax (Tmax)

    Time frame: Up to approximately 25 months

07

Study locations

44 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Sep 2027, 33 months after the start.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 33 months is below that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2024
First posted
Nov 8, 2024
StartActual
Dec 20, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06679985
Lead sponsor
Coherus Oncology, Inc.
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Dec 20, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Study Director
study director · Coherus Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Casdozokitug

Start the discussion